Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E editorial

This article was originally published in The Tan Sheet

Executive Summary

Results of a recent study finding increased risk of all-cause mortality associated with long-term use of high doses of vitamin E is "surprising," according to E. Robert Greenberg, MD, Dartmouth Medical School. Greenberg authored an editorial that accompanies a study in the Jan. 4 Annals of Internal Medicine; the trial was published early online (1"The Tan Sheet" Nov. 15, 2004, p. 13). "I am not totally convinced that the authors have isolated the effects of vitamin E from those of other supplements, since 10 of the 19 trials in the meta-analysis involved provision of vitamin E together with other nutritional supplements," he says. Still, Greenberg agrees with the authors' conclusion that vitamin E supplementation is unwarranted based on "ample evidence" that shows "no favorable health effects"...

You may also be interested in...



Vitamin E Dose Increases Linked To Rise In Risk Of Death – Study

Negative results from a vitamin E study showing high doses of the supplement may lead to a greater risk of all-cause mortality increase industry anticipation of findings from ongoing prospective antioxidant trials

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel